Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

Rhea-AI Summary

Disc Medicine (NASDAQ:IRON) appointed Lisa Amaya Price, MBA as Chief Human Resources Officer effective January 12, 2026.

Ms. Amaya Price has 25+ years of HR and organizational leadership experience at commercial-stage and large life-science companies. Disc granted an inducement award consisting of: an option for 37,500 shares (exercise price = closing price on grant date), an RSU for 25,000 shares, and a supplemental RSU for 4,000 shares.

Vesting: the option vests 25% on January 12, 2027, then monthly over 36 months; the RSU vests 25% annually starting February 15, 2026; the supplemental RSU vests quarterly in eight 12.5% installments starting February 15, 2026.

News Market Reaction

-4.53%

1 alert

-4.53% News Effect

On the day this news was published, IRON declined 4.53%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Option Award size: 37,500 shares RSU Award size: 25,000 shares Supplemental RSU size: 4,000 shares +5 more

8 metrics

Option Award size 37,500 shares Inducement stock option grant to new CHRO on Jan 12, 2026

RSU Award size 25,000 shares Primary restricted stock unit award to new CHRO

Supplemental RSU size 4,000 shares Supplemental restricted stock unit award to new CHRO

Experience more than 25 years HR and organizational leadership experience of new CHRO

Option vesting schedule 25% then 36 monthly installments Option Award vesting starting Jan 12, 2027, subject to service

RSU vesting schedule 4 annual installments of 25% RSU Award vests on Feb 15 each year from 2026 to 2029

Supplemental RSU vesting 8 quarterly installments of 12.5% Supplemental RSU Award vesting commencing Feb 15, 2026

Market cap $2,949,797,659 Market capitalization before the HR appointment news

Market Reality Check

Price: $77.32 Vol: Volume 475,667 is below t...

normal vol

$77.32 Last Close

Volume Volume 475,667 is below the 20-day average of 650,878, suggesting limited trading attention pre-news. normal

Technical Shares at $79.02 were trading above the 200-day MA of $64.04 before this announcement.

Peers on Argus

While IRON was down 1.45%, peers showed mixed moves: AGIO up 0.78%, but TARS, AR...

While IRON was down 1.45%, peers showed mixed moves: AGIO up 0.78%, but TARS, ARQT, TVTX, and OCUL were negative, pointing to a stock-specific rather than uniform sector move.

Common Catalyst Several biotechnology peers, including ARQT and AGIO, also issued strategic priority news, suggesting a broader period of corporate updates but not a clearly synchronized price move.

Historical Context

5 past events · Latest: 2026-01-07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-01-07	Conference presentation	Positive	+4.6%	Announcement of CEO presentation at J.P. Morgan Healthcare Conference.
2025-11-06	Earnings and NDA	Positive	-1.5%	Q3 2025 results, NDA submission for bitopertin, extended cash runway.
2025-11-03	Clinical data preview	Positive	-1.8%	Planned ASH presentations for DISC-0974 and DISC-3405 Phase 2 data.
2025-10-31	Investor conferences	Neutral	+0.6%	Participation in multiple November 2025 healthcare investor conferences.
2025-10-21	Equity offering	Negative	-1.1%	Pricing of $250M upsized public offering of stock and pre-funded warrants.

Pattern Detected

Recent history shows that clearly positive clinical and earnings updates sometimes coincided with short-term share declines, while neutral conference participation news often aligned with modest gains.

Recent Company History

Over the last few months, Disc Medicine issued multiple updates, including participation at major conferences on Jan 14, 2026 and November 2025 investor events, plus an NDA submission and strong cash position reported on Nov 6, 2025. The company also completed an upsized equity offering priced at $84.00 on Oct 21, 2025. Against this backdrop of financing and late-stage pipeline activity, today’s HR leadership appointment fits into scaling for potential commercialization and organizational growth.

Market Pulse Summary

This announcement adds an experienced Chief Human Resources Officer with more than 25 years of leade...

Analysis

This announcement adds an experienced Chief Human Resources Officer with more than 25 years of leadership background, supported by an inducement package of 37,500 option shares and 29,000 RSUs vesting over several years. It complements Disc Medicine’s recent NDA submission, clinical milestones, and financings aimed at commercialization. Investors may watch how leadership additions translate into hiring, organizational scalability, and execution on late-stage pipeline and launch objectives.

Key Terms

clinical-stage biopharmaceutical, restricted stock unit, exercise price, inducement equity award, +2 more

6 terms

clinical-stage biopharmaceutical medical

"a clinical-stage biopharmaceutical company focused on the discovery, development, and"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

restricted stock unit financial

"a restricted stock unit award for 25,000 shares of Common Stock (the “RSU Award”)"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

exercise price financial

"at an exercise price equal to the closing price of the Common Stock on the date"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

inducement equity award financial

"granted to Ms. Amaya Price an inducement equity award comprised of (i) an option"

An inducement equity award is stock or stock-based compensation granted to a new hire as a signing incentive—think of it as a pay package that uses company shares instead of cash. Investors care because it can dilute existing ownership, signal how a company values the new recruit, and align that person’s interests with shareholders; like a signing bonus paid in shares, it affects future share count and management incentives.

Nasdaq Listing Rule 5635(c)(4) regulatory

"with Disc in accordance with Nasdaq Listing Rule 5635(c)(4). While the inducement"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock option financial

"outside of Disc’s Amended and Restated 2021 Stock Option and Incentive Plan, the award"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company’s Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple commercial-stage companies.

“As we move towards commercialization, we have meaningfully increased hiring to support these efforts and Lisa will play a central role in building a strong, scalable organization by attracting, developing, and retaining exceptional talent across the business,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “Her leadership will be instrumental as we continue to strengthen our capabilities and prepare the company for long-term success.”

“I am excited to join Disc at this pivotal time for the company. The opportunity to help build and scale a team while preparing to deliver a much-needed therapy to patients with significant unmet needs is incredibly motivating,” said Ms. Amaya Price. “I look forward to partnering across the organization to support our people and culture as we enter this next phase of growth.”

Ms. Amaya Price joins Disc Medicine from Deciphera where she served as SVP and Chief HR Officer, helping lead the company’s integration into ONO Pharmaceuticals. Prior to this, she was the Chief People Officer at LGC Group, a private-equity global life science tools company with over 4,000 employees worldwide. Ms. Amaya Price was also a senior HR leader at Scholar Rock as well as Takeda Pharmaceuticals where she led organizational design and talent selection related to the acquisition of Shire Pharmaceuticals. Prior to Takeda, she spent 8 years at Biogen, serving in various positions of increasing responsibility, including most recently Senior Director, Human Resources of R&D.  Earlier in her career, she held human resource leadership positions at Interpublic Group, Inc., Metro International S.A., and American Financial Systems, Inc.  Ms. Amaya Price received a BA from Bard College, an MA from Simmons College, and an MBA from F.W. Olin Graduate School of Business at Babson College.       

In connection with Ms. Amaya Price’s appointment, on January 12, 2026, Disc granted to Ms. Amaya Price an inducement equity award comprised of (i) an option to purchase 37,500 shares (the “Option Award”) of Disc’s common stock (“Common Stock”), at an exercise price equal to the closing price of the Common Stock on the date of grant, (ii) a restricted stock unit award for 25,000 shares of Common Stock (the “RSU Award”), and (iii) a restricted stock unit award for 4,000 shares of Common Stock (the “Supplemental RSU Award” and, together with the Option Award and the RSU Award, the “Inducement Award”). The Option Award shall vest 25% on January 12, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service through the applicable vesting date. The RSU Award shall vest in equal installments of 25% each on the first, second, third, and fourth anniversaries of February 15, 2026, subject to continued service through the applicable vesting date. The Supplemental RSU Award shall vest in eight quarterly installments of 12.5% each commencing on February 15, 2026, subject to continued service through the applicable vesting date. The Inducement Award was approved by the Compensation Committee of Disc’s Board of Directors and was made as an inducement material to the employee entering into employment with Disc in accordance with Nasdaq Listing Rule 5635(c)(4). While the inducement award was granted outside of Disc’s Amended and Restated 2021 Stock Option and Incentive Plan, the award is subject to terms and conditions substantially consistent with those set forth under such plan.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Disc Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s commercialization plans and Disc’s expectations for the chief human resources officer position. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com 

Investor Relations Contact

Christina Tartaglia
Precision AQ
Christina.tartaglia@precisionaq.com 

FAQ

Who is Lisa Amaya Price and what role did Disc Medicine (IRON) appoint her to on January 12, 2026?

Lisa Amaya Price was appointed Chief Human Resources Officer at Disc Medicine effective January 12, 2026.

What inducement equity awards did Disc Medicine (IRON) grant Lisa Amaya Price on January 12, 2026?

She received an option to purchase 37,500 shares, an RSU for 25,000 shares, and a supplemental RSU for 4,000 shares.

What are the vesting terms for the option award granted to Lisa Amaya Price by Disc Medicine (IRON)?

The option vests 25% on January 12, 2027 with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service.

When do the RSU awards granted to Lisa Amaya Price by Disc Medicine (IRON) vest?

The 25,000-share RSU vests in four annual 25% installments beginning February 15, 2026; the 4,000-share supplemental RSU vests in eight quarterly 12.5% installments beginning February 15, 2026.

Under what Nasdaq rule was Lisa Amaya Price’s inducement award approved for Disc Medicine (IRON)?

The award was approved as an inducement material to employment in accordance with Nasdaq Listing Rule 5635(c)(4).